- Home
- TASK vs CSTL Comparison
TASK vs CSTL Comparison
Compare TASK & CSTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TASK | CSTL |
|---|---|---|
| Founded | 2008 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | Medical Specialities |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 969.3M | 806.3M |
| IPO Year | 2021 | 2019 |
Fundamental Metrics
Financial Performance| Metric | TASK | CSTL |
|---|---|---|
| Price | $10.18 | $25.38 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 6 |
| Target Price | $14.90 | ★ $47.17 |
| AVG Volume (30 Days) | ★ 658.4K | 397.3K |
| Earning Date | 01-01-0001 | 05-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 120.00 | N/A |
| EPS | ★ 1.10 | N/A |
| Revenue | N/A | ★ $344,229,000.00 |
| Revenue This Year | $6.12 | $2.10 |
| Revenue Next Year | $6.77 | $12.63 |
| P/E Ratio | $9.39 | ★ N/A |
| Revenue Growth | N/A | ★ 3.66 |
| 52 Week Low | $9.55 | $14.59 |
| 52 Week High | $18.39 | $44.28 |
Technical Indicators
Market Signals| Indicator | TASK | CSTL |
|---|---|---|
| Relative Strength Index (RSI) | 43.06 | 26.28 |
| Support Level | $9.78 | $21.77 |
| Resistance Level | $11.76 | $34.97 |
| Average True Range (ATR) | 0.50 | 1.38 |
| MACD | -0.02 | -0.09 |
| Stochastic Oscillator | 12.66 | 7.96 |
Price Performance
Historical ComparisonAbout TASK TaskUs Inc.
TaskUs Inc is a provider of outsourced digital services and next-generation customer experience to the world-wide Game-changing companies, helping its clients represent, protect and grow their brands. It serves clients in the fastest-growing sectors, including social media, e-commerce, gaming, streaming media, food delivery and ridesharing, HiTech, FinTech and HealthTech.
About CSTL Castle Biosciences Inc.
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. The company derives revenues through the delivery of test reports for its molecular diagnostic tests.